The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1). Methods: The study included 448 patients with postmenopausal OP. Patients were randomly assigned into six treatment groups each with a permutation of the treatment sequence (ABC, BCA, etc.) in the crossover phase (3x1 week) and randomized to 23 weeks of either the daily flexible (either regimen A, B or C) or fixed timing (only regimen A, B, or C) in the patient' s preference phase. Urinary NTX-1 was tested. Results: A total of 433 patients participated in the patient' s preference phase (49.7% preferred flexible and 50.3% fixed timing). There was no significant difference between the proportion of responders who were both compliant and persistent in the flexible (54.4%) and fixed regimens (53.7%) (p=0.8803). A significant difference between the flexible and fixed regimens was seen in persistence in favor of the flexible regimen (p=0.0306). There was no significant difference between the flexible and fixed regimens in terms of compliance (p=0.4611). Change in urinary NTX-1 did not show any difference between the two regimens. At the final visit, 51% of patients in the flexible and 55% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440). Conclusion: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP.
Medications for the treatment of postmenopausal osteoporosis (OP) require years of persistence and proper compliance to successfully achieve the goal of reducing fracture risk. Increased fracture risks of 30% [1] or 46% [2] with noncompliance and 30% to 40% with non-persistence [1] have been reported in systematic reviews and meta-analyses dealing with patients receiving OP medications. Therefore, patient compliance and persistence in taking of OP medications remain an important issue that may affect treatment efficacy. However, compliance and persistence with OP treatments are poor, [3] with compliance rates ranging from 0.46 to 0.64 as assessed using the medication possession ratio (MPR) and persistence rates for one year ranging from 26.1% to 55.7% for patients receiving daily bisphosphonates. [4] According to a survey investigating why OP patients do not continue with bisphosphonates, side effects and inconvenience-related reasons including the strict regimen that interferes ORIGINAL ARTICLE Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study with eating and drinking as well as with the taking of other medications, were reported to be among the most commonly-referred factors. [5] Among bisphosphonates, risedronate at a daily dose of 5 mg has been shown to reduce the risk of fracture, [6] [7] [8] [9] [10] and can be administered in one of three different timing regimens. In addition to the traditional before breakfast dosing of other oral bisphosphonates, daily risedronate can also be administered in a flexible way allowing patients to choose to take their medications 'in-between meals' or 'before bedtime' freely every day. Three studies exploring the effects of risedronate dosing at a time other than before breakfast on bone mineral density (BMD) and/or on bone turnover markers (BTMs) [11] [12] [13] [14] [15] have provided information on compliance [13] [14] [15] while two gave information on persistence only. [11, 12] Therefore, little information is available on patients' level of compliance and persistence with instructions to take medication at specific times of day or within specified amounts of time in relation to food intake. The aim of this study was to examine the compliance, persistence and preference between a fixed or flexible dosing regimen of daily risedronate in patients with postmenopausal OP.
Patients and Methods
The study included 448 women with postmenopausal OP enrolled in 10 centers in Turkey and 9 centers in Poland and treated with risedronate 5 mg daily, supplemented with 1000 mg of calcium and 400 IU of vitamin D, for 26 weeks. Inclusion criteria were as follows: ambulatory women aged 55 to 85 years and appropri-month within six months of entry to the study or any use within three months of beginning risedronate, history of cancer, known hypersensitivity to bisphosphonates and/ or excipients, likelihood of requiring treatment during the study period with drugs not permitted by the study protocol, hypocalcaemia, and history of alcohol abuse.
Patients were instructed to take risedronate while in an upright position with a glass of plain water, either a minimum of 30 minutes before the first food or drink of the day, or at least two hours apart from any food or drink intake at any other time of the day, or at least 30 minutes before going to bed/lying down.
The study protocol was approved by independent ethics committees in Turkey and Poland. Written informed consent was obtained prior to the conduct of any study-related procedures.
This crossover study comprised a screening phase (2 to 4 weeks) and a treatment phase (26 weeks), for a total of 5 visits. In the screening phase, the period between screening (Visit 1) and the baseline (Visit 2), patients were given 1000 mg of calcium and 400 IU of vitamin D. The treatment phase consisted of a crossover phase (from Visit 2 to Visit 3 at three weeks) and a patient' s preference phase (from Visit 3 until Visit 5 at 26 weeks). For treatment in the crossover phase, each subject was given a container with two blisters of 14 tablets of risedronate and was randomly assigned to one of six different treatment groups, each of which had three treatment sequences (ABC, BCA, etc.), using a computer-generated randomization schedule. The timing regimens were; A: before breakfast, B: in-between meals, or C: before Timing Regimens A=taken "before breakfast", B=taken "in-between meals", C=taken "before bedtime" "Total daily flexible timing" = Timing A or B or C can be chosen freely every day by the subject. "Fixed timing" = One timing regimen A, B or C is chosen for the entire phase. ate for OP treatment based on the investigator' s judgment (a T-score of ≤-2.5 of the spine and/or hip or ≤-1 plus low trauma fractures as measured by dual-energy X-ray absorptiometry) willing to participate in the study. Patients presenting at screening with any of the following were excluded: evidence of clinically significant organic or psychiatric disorder, any mental condition causing inability to understand the nature and possible consequences of the study, abnormal laboratory parameters (including renal or hepatic insufficiency, gastrointestinal disease), use of oral and parenteral glucocorticoids (≥5 mg prednisone or equivalent/day) for more than one bedtime. At the end of the third crossover sequence, on Visit 3, each subject was given a container of risedronate with six blisters of 14 tablets for treatment for Week 4 to Week 13 and assigned (based on preference) to 23 weeks of either daily flexible (regimen A, B, or C chosen freely each day) or daily fixed timing (regimen A, B, or C chosen for the remaining study period) groups. At Visit 4, patients were given their last container with seven blisters of 14 tablets for treatment for Weeks 14 to 26 (Fig.  1 ). The number of tablets returned at each study visit was recorded on the case report form. Analysis of urine samples for N-terminal telopeptide of Type 1 collagen (NTX-1) was performed using Os-teomark® NTX-1 Point-of-Care (Ostex International Inc., Seattle, WA, USA) [16] at the baseline, 13 th and 26 th weeks at each study center in Poland (with communication of the results to the subjects). These tests were not performed in the Turkish study centers due to difficulties in supplying the NTX-1 device.
Each subject completed a Subject' s Preference Questionnaire at the baseline, 3 rd and 5 th visits along with a questionnaire on subjects' opinion of the risedronate treatment.
Frequency of all treatment-emergent adverse events (TEAEs) was summarized by body system and preferred term including summaries of the severity as mild, moderate, or severe, and relationship to the study drug of all TEAEs. Compliance was defined as >50% dose taken and was measured by tablet count based on the collected study medication at visits 3, 4 and 5. Compliance was calculated as follows: % compliance=[#of tablets supplied-#of tablets returned]/#of tablets to have been taken x 100.
Persistence was defined as the continuation of treatment at Week 26.
Response was defined as a composite of the subject' s compliance and persistence. A subject being both compliant and persistent at Week 26 was considered a responder.
Statistical analyses were performed using the SAS software v.8.2 (SAS Institute Inc., Cary, NC, USA) for all patients and by country, for the primary intension-totreat (ITT) and the per protocol (PP) analysis sets. The chi-square and Cochran-Mantel-Haenszel tests were used for the analysis of categorical data, while numerical data (relevant to NTX-1) were analyzed using analysis of covariance (ANCOVA). Statistical significance was set at a p value of ≤0.05.
Results
A total of 448 patients participated in the first, crossover phase (Fig. 2 ). Of these, 433 continued in the second, patient preference phase and 215 (49.7%) chose the flexible regimen and 218 (50.3%) the fixed regimen. In the fixed regimen, 151 (70.2%) opted for regimen A (p=0.0001). Overall and country specific compliance, persistence and response rates for the primary ITT group are shown in Table 1 . The persistence rate in the flexible regimen (86.0%) was significantly higher than that of the fixed regimens (78.9%) (p=0.0306). The difference in terms of compliance between groups was not statistically significant (p=0.4611). In the fixed dosing group, patients taking their medication before bedtime had higher compliance and persistence rates. The proportion of responders did not differ between the two dosing regimens (54.4% vs. 53.7%) (p=0.8803), however, was higher for regimen C than those for regimen A and B within the fixed timing group.
At the final visit, 50.8% of patients in the flexible and 55.2% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440). Patients' opinion of the risedronate regimen is shown in Table 2 . There was no difference between fixed and flexible dosing in the efficacy of risedronate on the decrease of BTMs as shown by change from baseline in NTX-I levels at either Visit 4 or Visit 5 ( Table 3) .
Frequencies of all TEAEs are summarized in Table 4 .
Discussion
Our findings revealed that, apart from a significantly higher rate in persistence noted in patients under the flexible regimen, flexible and fixed dosing of daily risedronate therapy revealed similar findings in postmenopausal osteoporotic women in terms of compliance, responder and patient preference rates as well as efficacy on reduction in BTMs. Data on 6-month compliance rates in studies assessing before-breakfast dosing of bisphosphonates are inconsistent. A trial comparing the effects of once-monthly versus once-daily risedronate use in postmenopausal OP reported a compliance level of >97% using pill counts. [17] Studies using healthcare claims databases reported compliance rates of 70% (with an MPR ≥80%), [18] 40% (with an MPR ≥80%), [19] 75% (for those with an MPR >50%), [20] 61.6% and 55.6% (with an MPR≥80% in those with and without a previous fracture, respectively), [21] and 78.5% (for those with an MPR ≥50%. [22] The overall percentage of compliant patients in this study (approximately 60% in both regimens) was lower than that reported in a randomized clinical trial [17] or in observational database studies [18, 20, 22] based on drug dispensing data reflecting a real-world setting. However, it is difficult to make comparisons between our results and those studies defining compliant subjects with an MPR of 80%. [18, 19, 21] The difference between studies in terms of MPR definitions, the likelihood of cumulative compliance levels with a variety of medications for OP, and the compliance rates in patients with or without a previous fracture can be considered amongst the factors compromising the comparison. The findings of the IMPACT study indicating more patients in the before-breakfast dosing being compliant compared with flexible dosing of oral risedronate 5 mg daily [15] were in contradiction with those of ours being similar in both regimens.
The percentage of patients who persisted with treatment also vary in the literature, ranging from 40 to 71%. [19, 21, [23] [24] [25] [26] [27] [28] While the overall persistence levels in the flexible (86.0%) and fixed (78.9%) regimen groups in this trial were higher than those in the literature, the differences might be due to the difference in methodology between clinical studies and a real-world setting. Siris et al. found that an MPR of ≥50% was associated with substantial fracture reduction. [29] Similar results have been seen with bisphosphonates in compliant and/or persistent patients in both randomized clinical trials and real world practice in terms of fracture risk reduction. [30] In the literature, NTX-1 monitoring has been associated with improved persistence [31] and adherence. [32] In our study, NTX-1 monitoring was performed in the Polish patients but not in the Turkish patients, and may account for the higher compliance and persistence rates in the Polish patients. However, as another study reported no differences in persistence rates between patients who received BTM results and those who did not, [33] the role of NTX-1 monitoring in the reinforcement of persistence and/or compliance remains a speculation. In addition, the discrepancy between the results in Turkey and Poland may also be attributed to geographical differences. [15] Regarding the efficacy of risedronate on the decrease as measured by urinary NTX-1 testing, there was no significant adjusted difference between the baseline and 6 th month findings of flexible and fixed daily dosing regimens. However, Hosking et al. [13] reported greater changes in NTX-1 at 6 months (approximately -35%) with between-meal dosing of daily risedronate than those observed in our study.
The before bedtime subgroup in the fixed dosing regimen in our study had the highest percentage of responders and the in-between meals subgroup the lowest. Mitchell et al. reported that risedronate absorption was comparable when administered either before breakfast or before bedtime and implied a similar effectiveness. [34] Therefore, it can be extrapolated that before bedtime dosing is an alternative means to achieve the desired efficacy.
The risedronate regimen used was rated as excellent or very good by more than half of the patients in both the flexible and fixed regimens, indicating treatment satisfaction. Barrett-Connor et al. pointed to the lower likelihood of medication discontinuation in women with higher satisfaction. [35] Adverse events experienced with risedronate in this study were few and mild in nature, mainly affecting the upper gastrointestinal system and were comparable with those in previous studies using flexible dosing. [11] [12] [13] [14] [15] There were several limitations to this study. The response rate in the fixed dosing group was considerably lower than 70% and may weaken the comparison between groups. While a sample size of around 460 patients was planned, only 448 patients were enrolled and 397 completed the study. However, given the data available from the existing sample size, it can be concluded that the flexible regimen is not significantly different than the fixed regimen in terms of compliance. Other limitations may include the lack of categorical evaluation of MPRs of ≥80%, which might allow for a more detailed assessment of compliance and facilitate comparison with some other studies. However, the cut-off point of 50% utilized in this study is a commonly used definition of compliant use. [36] The measurement of change in BMD at six months would have also added value in terms of efficacy of different timing of risedronate use if it had been measured. Failure to measure urinary NTX-1 in Turkey may have also affected the overall compliance and persistence rates. We may also speculate that the assessment of the effects of influencing factors on compliance and/ or persistence such as prior lack of adherence with other medications, concerns about side effects, beliefs about OP and associated disability, benefits of OP medications and use of alcohol [37, 38] might have given more insights on the rates of compliance and persistence if those assessments had been performed. In conclusion, flexible dosing resulted in better persistence rates than fixed dosing but did not affect compliance rates. A similar percentage of patients preferred daily flexible and fixed dosing, and both regimens were rated as excellent or very good by the patients. Alternate timing for the use of risedronate may assist patients with difficulty following the traditional before-breakfast dosing regimen and offer an option which could easily be incorporated into the individuals' personal schedules. However, because approved treatment regimens vary between countries, these findings may not be applicable worldwide. Additional large scale studies including categorical evaluation of MPR, measurement of change in BMD and the assessment of the additional factors likely to influence compliance and/or persistence will enable more accurate assessment of compliance and persistence with daily risedronate regimens in patients with postmenopausal OP. Acknowledgement: We also gratefully acknowledge the dedicated investigators of the FLINT-ACT (FLexible INTake of ACTonel®) Study. In addition to Drs. Aydan ORAL and Roman LORENC, the following were the participating investigators of the FLINT-ACT Study: Dilsad SINDEL, Ayse YALIMAN, Fikret TUzUN, Ulku AkARIRMAk, Sansin TUzUN, Gulseren AkYUz, Nurdan PAkER, Peyman YAL-CIN, zafer HASCELIk, Vesile SEPICI, Yesim kI-RAzLI, Simin HEPGULER, Sema ONCEL, and Tiraje TUNCER (from the ten centers in Turkey); and Edward CzERWIńSkI, Stanislaw RADOWICkI, Janusz BADURSkI, Jaroslaw DESzCzYńSkI, Szymankiewicz-POzNAń, Alina WARENIk, Andrzej WIECEk, Hanna CHWALIńSkA, and Tadeusz GAźDzIk (from the nine centers in Poland).
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